Gufic Biosciences growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+15.2%+1.6%—
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+12.4%−7.7%—
+6.0%−11.8%—
−7.8%−19.1%—
−7.9%−20.5%—
+14.8%+7.0%+26.9%
+10.6%+12.9%+53.1%
−63.3%+1,743.1%+71.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GUFICBIO₹423.75

Gufic Biosciences Limited

· Pharma & Health
₹ CrorePeersRPGLIFEUNICHEMLABGUJTHEMORCHPHARMASMSPHARMAINDSWFTLABFDCIOLCPMcap ₹4,249 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth——+1.6+15.2—
EBITDA Growth——-7.7+12.4—
EBIT Growth——-11.8+6.0—
Net Income Growth——-19.1-7.8—
EPS Growth——-20.5-7.9—
Total Assets Growth—+26.9+7.0+14.8—
Total Equity Growth—+53.1+12.9+10.6—
Cash from Operations Growth—+71.9+1,743.1-63.3—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.